Biohaven Ltd.

Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused ...

Biohaven shares surged 6.65% in regular trading and 3.42% in after-hours trading following an investor presentation at the J.P. Morgan Healthcare Conference. The company presented Phase 1 data for BHV-1400 showing significant reductions in IgA nephropathy markers and clinical improvements in patients. Multiple catalysts are expected in 2026, incl...

U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. E...

The migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.

Biohaven's Chief Accounting Officer George Clark purchased 17,000 shares despite the company facing challenges, including FDA rejection of its lead drug and significant quarterly losses. The stock is currently not recommended for investment due to precarious business outlook.